Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Incyte Corp INCY

Healthcare Biotechnology
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland and its other offices across Europe, as well as its Japanese office in Tokyo and its Canadian headquarters in Montreal. It operates... see more

Recent & Breaking News (NDAQ:INCY)

Incyte Presents Significant Progress in its Development Portfolio

Business Wire January 11, 2016

Incyte and AstraZeneca Announce New Lung Cancer Clinical Trial Collaboration

Business Wire January 11, 2016

Incyte to Present at the 34th Annual J. P. Morgan Healthcare Conference

Business Wire December 14, 2015

Phase 3 RESPONSE-2 Study of Jakafi® (ruxolitinib) Meets Primary Endpoint

Business Wire December 5, 2015

Two Phase 3 Studies Reinforce Sustained Benefits of Treatment with Jakafi® (ruxolitinib) in Patients with Myeloproliferative Neoplasms (MPNs)

Business Wire December 5, 2015

Incyte's Jakafi® (ruxolitinib) to be Featured in over 60 Abstracts at ASH Annual Meeting

Business Wire November 30, 2015

Lilly and Incyte Announce Patients Treated with Baricitinib Demonstrated Significant Improvement in Signs and Symptoms of Rheumatoid Arthritis Compared with Methotrexate

Canada NewsWire November 7, 2015

Detailed Results Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis

Canada NewsWire November 7, 2015

Epacadostat in Combination with Pembrolizumab Demonstrates Promising Clinical Activity in Multiple Advanced Cancers

Business Wire November 3, 2015

Incyte Reports 2015 Third-Quarter Financial Results and Updates Shareholders on Key Clinical Programs

Business Wire November 3, 2015

Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase 3 Data

PR Newswire October 27, 2015

Biotech ETFs Get More Refined With Debut Of Cancer Immunotherapy Fund

Benzinga.com  October 14, 2015

Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study

PR Newswire October 14, 2015

Incyte to Report Third Quarter Financial Results

Business Wire October 13, 2015

Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda® (pembrolizumab) as First-line Treatment for Advanced Melanoma

Business Wire October 13, 2015

Data at SITC Annual Meeting to Highlight Progress of Incyte's Immuno-oncology Portfolio

Business Wire October 2, 2015

UPDATE -- Incyte Corporation to Join the NASDAQ-100 Index Beginning October 7, 2015

GlobeNewswire September 30, 2015

Incyte Corporation to Join the NASDAQ-100 Index Beginning October 7, 2015

GlobeNewswire September 29, 2015

Baricitinib Superior to Methotrexate in Reducing Signs and Symptoms in Pivotal Phase 3 Study in Patients with Rheumatoid Arthritis

PR Newswire September 29, 2015

Incyte to Present at the Leerink Partners Inaugural Immuno-Oncology Roundtable Conference

Business Wire September 15, 2015